Impact of admission hyperglycemia on short and long-term prognosis in acute myocardial infarction: MINOCA versus MIOCA.
Pasquale PaolissoAlberto FoàLuca BergamaschiFrancesco AngeliMichele FabrizioFrancesco DonatiSebastiano TonioloChiara ChitiAndrea RinaldiAndrea StefanizziMatteo ArmillottaAngelo SansonettiIlenia MagnaniGianmarco IannopolloPaola RucciGianni CasellaNazzareno GalièCarmine PizziPublished in: Cardiovascular diabetology (2021)
aHGL was identified as a strong predictor of adverse short- and long-term outcomes in both MIOCA and MINOCA, regardless of diabetes. aHGL should be considered a high-risk prognostic marker in all AMI patients, independently of the underlying coronary anatomy. Trial registration data were part of the ongoing observational study AMIPE: Acute Myocardial Infarction, Prognostic and Therapeutic Evaluation. ClinicalTrials.gov Identifier: NCT03883711.
Keyphrases
- acute myocardial infarction
- percutaneous coronary intervention
- left ventricular
- coronary artery disease
- end stage renal disease
- type diabetes
- ejection fraction
- coronary artery
- emergency department
- newly diagnosed
- cardiovascular disease
- clinical trial
- electronic health record
- study protocol
- heart failure
- machine learning
- aortic stenosis
- big data
- phase iii
- metabolic syndrome
- randomized controlled trial
- insulin resistance
- open label
- adverse drug
- clinical evaluation